Hydroxyfasudil HCl (also called HA1100 HCl), a metabolite of Fasudil, is a potent Rho-kinase inhibitor and vasodilator.

Y-27632 2HCl (Y27632; Y2 7632), the dihydrochloride salt of Y-27632, is a novel, potent and selective inhibitor of ROCK1 (p160ROCK) with potential antifibrotic and anticancer activity.

Netarsudil 2HCl (formerly AR13324; AR 13324; AR-13324; Rhopressa), the dihydrochloride salt of Netarsudil, is ROCK inhibitor with antihypertensive activity and the potential for glaucoma treatment.

THZ1 (THZ-1) is a novel, potent, selective and covalent/irreversible CDK7 inhibitor (IC50 = 3.2 nM) with anticancer activity.

Fasudil HCl (formerly known as HA1077; HA 1077; HA-1077), the hydrochloride salt of fasudil, is a potent multikinase inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with the potential to be used for the treatment of cerebral vasospasm.

Kobe0065 (Kobe 0065) is novel and potent inhibitor of the H-Ras-cRaf1 interaction which exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.

Belumosudil (formerly known as KD-025, ROCK inhibitor, and SLx-2119; trade name Rezurock) is a novel, potent, orally bioavailable, and selective small molecule ROCK2 inhibitor that has been approved by FDA in July 2021 for the treatment of chronic graft versus host disease (cGvHD).

GSK269962 HCl (also called GSK-269962A HCl), the hydrochloride salt of GSK 269962A, is a selective ROCK (Rho-associated protein kinase) inhibitor with potential antihypertensive and cardioprotective activity.

Y-39983 (also called Y-33075) is a novel, potent and selective inhibitor of Rho-associated coiled coil-forming protein kinase( ROCK ) with IC50 values of 3.6 nM, 0.42 μM and 0.81 μM for ROCK, PKC and CaMKII, respectively.

SAR407899 is a novel, potent, selective, and ATP-competitive ROCK inhibitor with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively.